LIGAND PHARMACEUTICALS INCORPORATED (LGND) Total liabilities 2016–2025
LIGAND PHARMACEUTICALS INCORPORATED (LGND) total liabilities at each fiscal year-end, per SEC filings.
$543.4MFY2025 · since FY2016: $230.7M → $543.4M
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | $543.4M | +388.1% |
| FY2024 | $111.3M | +29.0% |
| FY2023 | $86.3M | -47.8% |
| FY2022 | $165.2M | -65.3% |
| FY2021 | $476.4M | -27.0% |
| FY2020 | $652.8M | -10.3% |
| FY2019 | $727.7M | +4.0% |
| FY2018 | $699.9M | +177.3% |
| FY2017 | $252.4M | +9.4% |
| FY2016 | $230.7M | — |
Years the filer does not tag total liabilities directly are shown as reported total assets − reported shareholders’ equity at the same fiscal year-end.
Source: SEC XBRL filings · For reference only · Not investment advice
More LGND financial trends
LGND RevenueLGND Net incomeLGND Net marginLGND Gross profitLGND Gross marginLGND Operating incomeLGND Operating marginLGND Operating cash flowLGND Free cash flowLGND Capital expendituresLGND Return on equityLGND Stock buybacksLGND Dividends paidLGND Total assetsLGND Shareholders’ equityLGND overview →